AXNX:NSD-Axonics Modulation Technologies, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 45.90

Change

+0.62 (+1.37)%

Market Cap

USD 1.79B

Volume

0.33M

Average Target Price

USD 48.75 (+6.21%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+4.93 (+1.55%)

USD25.05B 14.49 68.43
PODD Insulet Corporation

+3.42 (+1.53%)

USD14.70B 773.39 143.86
LVGO Livongo Health, Inc

-2.85 (-2.03%)

USD14.25B N/A N/A
ABMD Abiomed, Inc

+7.11 (+2.67%)

USD12.00B 75.42 46.69
TNDM Tandem Diabetes Care, Inc

+2.09 (+1.93%)

USD6.60B N/A N/A
BRKR Bruker Corporation

+0.33 (+0.84%)

USD5.99B 36.51 18.69
SDC SmileDirectClub, Inc

+0.27 (+2.40%)

USD4.34B N/A N/A
IART Integra LifeSciences Holdings ..

-0.19 (-0.40%)

USD3.96B 160.06 27.46
WMGI Wright Medical Group N.V

+0.12 (+0.39%)

USD3.95B N/A 62.99
NUVA NuVasive, Inc

-0.06 (-0.12%)

USD2.56B 49.69 17.19

ETFs Containing AXNX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 65.64% 88% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.64% 88% B+ 88% B+
Trailing 12 Months  
Capital Gain 70.51% 84% B 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.51% 84% B 86% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.97% N/A N/A 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.97% N/A N/A 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 34.28% N/A N/A 40% F
Risk Adjusted Return 61.16% N/A N/A 78% C+
Market Capitalization 1.79B 84% B 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.82 44% F 22% F
Price / Cash Flow Ratio -21.44 80% B- 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -39.85% 49% F 27% F
Return on Invested Capital -43.94% 41% F 21% F
Return on Assets -20.65% 40% F 19% F
Debt to Equity Ratio 11.11% 77% C+ 74% C
Technical Ratios  
Short Ratio 11.11 10% F 10% F
Short Percent 18.58% 8% F 11% F
Beta -1.87 96% A 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector